The Diagnostic Value of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Apr 7, 2024
Trial Information
Current as of August 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special type of ultrasound called contrast-enhanced ultrasound (CEUS) to understand how blood flow in the kidneys changes when someone has acute kidney injury in the intensive care unit (ICU). The researchers want to see how the changes in kidney blood flow relate to overall blood flow in the body. This information could help doctors diagnose kidney problems more effectively in critically ill patients.
To participate in this study, individuals must be over 18 years old and have been admitted to the ICU within the last 24 hours, with a planned stay of at least two days. They should also have risk factors for acute kidney injury. However, people who have severe chronic kidney disease, are on dialysis, or have certain kidney-related issues will not be eligible. Participants will receive a contrast-enhanced ultrasound, which is a safe and painless procedure, to help gather important information about their kidney function during their time in the ICU.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\>18 years old
- • First admission to ICU \< 24h after admission and expected ICU stay ≥48 hours
- • Acute kidney injury risk factors (KDIGO 2012)
- • Contrast-enhanced ultrasound
- Exclusion Criteria:
- • Known severe chronic kidney disease (CKD≥ stage 4) or undergoing hemodialysis treatment
- • Kidney transplantation or renal malignancy
- • Terminal stage of malignant tumor
- • Pregnancy
- • Renal artery stenosis or renal vein thrombosis
- • The quality of CEUS images is poor, and quantitative analysis cannot be performed
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ligang Cui, Dr
Principal Investigator
Department of Ultrasound, Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported